{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:20:05Z","timestamp":1788477605779,"version":"build-2803163510"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007338","name":"Foundation for Barnes-Jewish Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007338","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.bone.2023.116788","type":"journal-article","created":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T02:14:00Z","timestamp":1683684840000},"page":"116788","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Drug-induced osteopetrosis"],"prefix":"10.1016","volume":"173","author":[{"given":"Michael P.","family":"Whyte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"McAlister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vandana","family":"Dhiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirmal Raj","family":"Gopinathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay K.","family":"Bhadada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2023.116788_bb0005","series-title":"Genetics of Bone Biology and Skeletal Disease","first-page":"507","article-title":"Sclerosing bone disorders, Chapter 29","author":"Boudin","year":"2018"},{"key":"10.1016\/j.bone.2023.116788_bb0010","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJMoa023110","article-title":"Bisphosphonate-induced osteopetrosis","volume":"349","author":"Whyte","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2023.116788_bb0015","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","article-title":"Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases","volume":"62","author":"Ruggiero","year":"2004","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.bone.2023.116788_bb0020","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jc.2004-0952","article-title":"Severely suppressed bone turnover: a potential complication of alendronate therapy","volume":"90","author":"Odvina","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2023.116788_bb0025","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1359\/jbmr.080511","article-title":"Bisphosphonate-induced osteopetrosis: novel bone modeling defects, metaphyseal osteopenia, and osteosclerosis fractures after drug exposure ceases","volume":"23","author":"Whyte","year":"2008","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2023.116788_bb0030","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/BF00350961","article-title":"Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta","volume":"16","author":"Devogelaer","year":"1987","journal-title":"Skelet. Radiol."},{"key":"10.1016\/j.bone.2023.116788_bb0035","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","article-title":"Cyclic administration of pamidronate in children with severe osteogenesis imperfecta","volume":"339","author":"Glorieux","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2023.116788_bb0040","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1148\/radiology.184.1.1609087","article-title":"Epi- and metaphyseal changes in children caused by administration of bisphosphonates","volume":"184","author":"Persijn","year":"1992","journal-title":"Radiology"},{"key":"10.1016\/j.bone.2023.116788_bb0045","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/00005792-199707000-00005","article-title":"Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis","volume":"76","author":"Brumsen","year":"1997","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bone.2023.116788_bb0050","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S0022-3476(99)70447-6","article-title":"Expanding role of bisphosphonate therapy in children","volume":"134","author":"Shoemaker","year":"1999","journal-title":"J. Pediatr."},{"issue":"5","key":"10.1016\/j.bone.2023.116788_bb0055","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s11914-020-00621-3","article-title":"Do bisphosphonates alleviate pain in children? A systematic review","volume":"18","author":"Celin","year":"2020","journal-title":"Curr Osteoporos Rep."},{"key":"10.1016\/j.bone.2023.116788_bb0060","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1136\/adc.86.5.356","article-title":"Soderhall S beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta","volume":"86","author":"Astrom","year":"2002","journal-title":"Arch. Dis. Child."},{"issue":"28","key":"10.1016\/j.bone.2023.116788_bb0065","first-page":"2","article-title":"Sustained beneficial effect of intravenous bisphosphonates after their discontinuation in children","volume":"22","author":"Waterhouse","year":"2007","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.bone.2023.116788_bb0070","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1177\/000992289903801201","article-title":"Bisphosphonates: from grandparents to grandchildren","volume":"38","author":"Srivastava","year":"1999","journal-title":"Clin. Pediatr. (Phila)"},{"key":"10.1016\/j.bone.2023.116788_bb0075","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1007\/s00198-007-0330-3","article-title":"Can bisphosphonate treatment be stopped in a growing child with skeletal fragility?","volume":"18","author":"Ward","year":"2007","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2023.116788_bb0080","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1359\/JBMR.050109","article-title":"Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement","volume":"20","author":"Letocha","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2023.116788_bb0085","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJMp038103","article-title":"Do bisphosphonates make children's bones better or brittle?","volume":"349","author":"Marini","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2023.116788_bb0090","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1056\/NEJMc062792","article-title":"Prolonged bisphosphonate release after treatment in children","volume":"356","author":"Papapoulos","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2023.116788_bb0095","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1359\/JBMR.040303","article-title":"Sclerotic metaphyseal lines in a child treated with pamidronate: histomorphometric analysis","volume":"19","author":"Rauch","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2023.116788_bb0100","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00247-004-1393-3","article-title":"Bone densitometry in pediatric patients treated with pamidronate","volume":"35","author":"Grissom","year":"2005","journal-title":"Pediatr. Radiol."},{"key":"10.1016\/j.bone.2023.116788_bb0105","first-page":"322","article-title":"The clinical and radiological assessment of cyclic intravenous pamidronate administration in children with osteogenesis imperfecta","volume":"46","author":"Adiyaman","year":"2004","journal-title":"Turk. J. Pediatr."},{"key":"10.1016\/j.bone.2023.116788_bb0110","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1542\/peds.111.3.573","article-title":"Intravenous bisphosphonate therapy in children with osteogenesis imperfecta","volume":"111","author":"Falk","year":"2003","journal-title":"Pediatrics"},{"key":"10.1016\/j.bone.2023.116788_bb0115","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1210\/jc.2005-0057","article-title":"Long-term safety of bisphosphonates","volume":"90","author":"Ott","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2023.116788_bb0120","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1056\/NEJMc062268","article-title":"Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis","volume":"355","author":"Armamento-Villareal","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2023.116788_bb0125","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1359\/jbmr.070609","article-title":"Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study","volume":"22","author":"Chapurlat","year":"2007","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2023.116788_bb0130","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00774-007-0771-y","article-title":"Pelvic insufficiency fracture associated with severe suppression of bone turnover by alendronate therapy","volume":"25","author":"Imai","year":"2007","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.bone.2023.116788_bb0135","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1172\/JCI0215952","article-title":"The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta","volume":"110","author":"Rauch","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bone.2023.116788_bb0140","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1542\/peds.2006-2023C","article-title":"Effects of pharmacologic agents on bone in childhood: an editorial overview","volume":"119","author":"Klein","year":"2007","journal-title":"Pediatrics"},{"key":"10.1016\/j.bone.2023.116788_bb0145","doi-asserted-by":"crossref","first-page":"638","DOI":"10.5435\/00124635-200611000-00006","article-title":"Bisphosphonate use in children with bone disease","volume":"14","author":"Hickey","year":"2006","journal-title":"J. Am. Acad. Orthop. Surg."},{"key":"10.1016\/j.bone.2023.116788_bb0150","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/07853890510007386","article-title":"Bisphosphonate treatment in osteogenesis imperfecta: which drug, for whom, for how long?","volume":"37","author":"Rauch","year":"2005","journal-title":"Ann. Med."},{"key":"10.1016\/j.bone.2023.116788_bb0155","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1210\/jc.2005-2413","article-title":"Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation","volume":"91","author":"Rauch","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2023.116788_bb0160","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.bone.2006.11.020","article-title":"Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta","volume":"40","author":"Rauch","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.bone.2023.116788_bb0165","first-page":"959","article-title":"Pamidronate lines","volume":"42","author":"Srinivasan","year":"2005","journal-title":"Indian Pediatr."},{"key":"10.1016\/j.bone.2023.116788_bb0170","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1002\/jbmr.5650111010","article-title":"Creatine kinase brain isoenzyme (BB-CK) presence in serum distinguishes osteopetroses among the sclerosing bone disorders","volume":"11","author":"Whyte","year":"1996","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2023.116788_bb0175","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.bone.2005.02.016","article-title":"Quantification of metaphyseal modeling in children treated with bisphosphonates","volume":"36","author":"Ward","year":"2005","journal-title":"Bone"},{"key":"10.1016\/j.bone.2023.116788_bb0180","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1359\/JBMR.051207","article-title":"Cyclical intravenous pamidronate treatment affects metaphyseal modeling in growing patients with osteogenesis imperfecta","volume":"21","author":"Land","year":"2006","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2023.116788_bb0185","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/adc.2006.096552","article-title":"Intravenous pamidronate treatment of infants with severe osteogenesis imperfecta","volume":"92","author":"\u00c5str\u00f6m","year":"2007","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.bone.2023.116788_bb0190","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/BF02555748","article-title":"Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat","volume":"38","author":"Schenk","year":"1986","journal-title":"Calcif. Tissue Int."},{"issue":"1","key":"10.1016\/j.bone.2023.116788_bb0195","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1136\/archdischild-2017-313234","article-title":"Efficacy and treatment costs of zoledronate versus pamidronate in paediatric osteoporosis","volume":"103","author":"Saraff","year":"2018","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.bone.2023.116788_bb0200","first-page":"365","article-title":"X-ray images of rare bone disease [R\u00f6ntgenbilder einer seltenen knochenerkrankung.]","volume":"51","author":"Albers-Sch\u00f6nberg","year":"1904","journal-title":"M\u00fcnchen medWehnschr."},{"issue":"6","key":"10.1016\/j.bone.2023.116788_bb0205","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s11914-022-00756-5","article-title":"Osteoclast recycling and the rebound phenomenon following denosumab discontinuation","volume":"20","author":"Kim","year":"2022","journal-title":"Curr. Osteoporos. Rep."},{"key":"10.1016\/j.bone.2023.116788_bb0210","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1359\/jbmr.081253","article-title":"Atypical femoral fractures, bisphosphonates, and adult hypophosphatasia","volume":"24","author":"Whyte","year":"2009","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2023.116788_bb0215","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/jbmr.253","article-title":"Sen HT van der meulen MCH, weinstein RS, whyte MP: atypical subtrochanteric and diaphyseal femur fractures: report of a task force of the American Society for Bone and Mineral Research","volume":"25","author":"Shane","year":"2010","journal-title":"J. Bone Miner. Res."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328223001217?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328223001217?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T18:07:01Z","timestamp":1757614021000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328223001217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":43,"alternative-id":["S8756328223001217"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2023.116788","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-induced osteopetrosis","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2023.116788","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116788"}}